Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus

Table 1 Demographic, clinical, and pathological features predicting overall survival in patients with proximal gastric carcinoma involving esophagus

Characteristics	Number of patients (%)	Months after surgery (mean ± SD)	P value	1-yr survival %	3-yr survival %	5-yr survival %
Age (yr)			0.108
< 70	97 (68.3)	30 ± 17		91.1	65.3	40.1
≥ 70	45 (31.7)	27 ± 19		77.0	49.3	17.3
Gender			0.594
Male	109 (76.8)	28 ± 17		71.1	61.1	23.1
Female	33 (23.2)	30 ± 18		88.3	60.1	48.1
Helicobacter pylori infection			0.400
Negative	80 (56.3)	30 ± 18		87.3	67.6	29.4
Positive	62 (43.7)	27 ± 17		87.1	50.8	32.3
Surgical modality			0.950
Partial gastrectomy	112 (78.9)	29 ± 18		85.7	68.6	35.1
Total gastrectomy	21 (14.8)	28 ± 18		76.2	65.3	0.0
Ivor-Lewis procedure	9 (6.3)	29 ± 17		89.2	60.6	34.3
Siewert type			0.444
Type II	116 (81.7)	29 ± 17		86.8	63.8	27.2
Type III	26 (18.3)	33 ± 19		88.5	50.2	40.2
Bormann’s type			0.380
Polypoid	2 (1.4)	27 ± 26		100.0	50.1	50.1
Fungating	17 (12.0)	34 ± 20		83.3	70.9	53.2
Ulcerated	96 (67.6)	28 ± 17		88.0	56.3	26.8
Flat	27 (19.0)	26 ± 18		86.5	66.6	29.6
Tumor size (cm)			0.087
< 3	19 (13.4)	30 ± 17		87.0	72.1	17.2
3.1-7.9	112 (78.9)	30 ± 17		89.7	61.5	38.5
> 8	11 (7.7)	18 ± 15		63.6	26.5	0.0
Surgical margin			0.165
Negative	126 (88.7)	30 ± 17		88.8	60.6	30.1
Positive	16 (11.3)	23 ± 19		74.5	66.2	33.1
Lymphovascular invasion			0.050
Negative	56 (39.4)	33 ± 18		90.9	65.6	31.2
Positive	86 (60.6)	27 ± 17		84.	57.6	31.7
Perineural invasion			0.003
Negative	55 (38.7)	35 ± 18		92.7	63.4	41.3
Positive	87 (61.3)	26 ± 17		83.6	59.4	19.3
Tumor differentiation			0.0003
Well	1 (0.7)	57		100.0	100.0	100.0
Moderately	70 (49.3)	34 ± 17		95.2	69.3	44.2
Poorly	70 (49.3)	24 ± 16		81.3	52.7	11.3
Undifferentiated	1 (0.7)	4		0.0	0.0	0.0
Tumor histopathology			0.548
Adenocarcinoma (nitric oxide synthase)	112 (78.9)	31 ± 17		89.6	71.0	34.2
Adenocarcinoma with micropapillary feature	24 (16.9)	24 ± 10		100	0.0	0.0
Adenosquamous carcinoma	9 (6.3)	28 ± 15		88.9	33.3	0.0
Mucinous carcinoma	9 (6.3)	24 ± 14		88.9	30.5	30.5
Signet ring cell carcinoma	23 (16.2)	23 ± 19		69.3	58.5	39.0
Carcinoma with neuroendocrine features	7 (4.9)	28 ± 17		100.0	50.0	25.0
Carcinoma with mixed types	37 (26.1)	24 ± 13		86.3	50.1	50.1
Pathologic T stage			0.400
1A	2	38 ± 27		100.0	50.0	50.0
1B	2	47 ± 3		100.0	100.0	100.0
2	12	27 ± 17		83.3	72.9	54.7
3	125	29 ± 17		87.0	59.8	29.2
4A	0	0		-	-	-
4B	1	18		100.0	0.0	0.0
Pathologic N stage			0.001
0	36	35 ± 17		94.4	72.0	53.5
1	22	32 ± 17		91.3	70.1	70.1
2	35	30 ± 17		85.3	64.7	15.9
3A	35	25 ± 17		85.3	57.4	14.4
3B	14	15 ± 9		70.7	41.3	10.3
Pathologic M stage			0.005
M0	130	28 ± 18		88.3	64.5	32.5
M1	12	12 ± 4		75.0	13.1	13.1
Overall stage			0.012
1A	4	42 ± 16		100.0	75.0	75.0
1B	7	30 ± 15		100.0	100.0	100.0
2A	26	34 ± 19		88.5	63.0	42.0
2B	26	32 ± 17		84.6	66.8	60.7
3A	29	31 ± 17		93.1	72.6	19.8
3B	29	27 ± 18		86.2	62.9	15.3
3C	9	18 ± 10		76.2	15.2	15.2
4	12	16 ± 9		75.0	13.1	13.1